{"ticker": {"uuid": "ce9a508d-020c-4944-9c1f-818ae486dd27", "symbol": "GALT", "name": "Galectin Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock", "summary": "Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., sold 16,250 shares of common stock for $83,284 on July 14, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options for the same number of shares at a lower price. Following the", "url": "https://www.investing.com/news/insider-trading-news/galectin-therapeutics-cmo-jamil-khurram-sells-83284-in-stock-93CH-4797135", "source_name": "Investing.com", "published_at": "2026-07-16T22:42:00", "published_display": "16 Jul 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan", "summary": "Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 each and subsequently sold all 16,250 shares at a weighted average price of $5.1252 on July 14, 2026. This transaction was conducted under a Rule 10b5-1 trad", "url": "https://www.stocktitan.net/sec-filings/GALT/form-4-galectin-therapeutics-inc-insider-trading-activity-cf346c04e766.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:42:00", "published_display": "16 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com", "summary": "This article reports on a Form 4 filing for Galectin Therapeutics Inc. on July 16, indicating a specific financial disclosure for the company. The stock symbol GALT is mentioned with a performance of -11.24%. The content primarily consists of market data and news headlines from I", "url": "https://ca.investing.com/news/stock-market-news/form-4-galectin-therapeutics-inc-for-16-july-93CH-4738612", "source_name": "Investing.com Canada", "published_at": "2026-07-16T21:42:00", "published_display": "16 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research", "summary": "Zacks Research has downgraded Galectin Therapeutics (NASDAQ:GALT) from \"hold\" to \"strong sell.\" This downgrade comes amidst mixed analyst ratings, with the company currently holding a consensus \"Reduce\" rating and a target price of $11.00. Galectin Therapeutics recently reported ", "url": "https://www.marketbeat.com/instant-alerts/galectin-therapeutics-nasdaqgalt-stock-rating-lowered-by-zacks-research-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T10:11:15", "published_display": "15 Jul 2026 10:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Galectin Therapeutics Inc. \u2013 NASDAQ:GALT", "summary": "This article from TradingView provides financial information for Galectin Therapeutics Inc. (NASDAQ: GALT). It specifically highlights the \"Price to book forward\" metric for the company. The rest of the content consists of navigation, market data sources, and copyright informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:11:15", "published_display": "15 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$Galectin Therapeutics (GALT.US)$", "summary": "This page is a community post on moomoo about Galectin Therapeutics (GALT.US). It appears to be a user-generated comment or discussion point, not a formal article or analysis. The content primarily consists of navigation and promotional elements for moomoo itself, with the core m", "url": "https://www.moomoo.com/community/feed/galectin-therapeutics-galt-us-116904507342857", "source_name": "Moomoo", "published_at": "2026-07-12T16:40:53", "published_display": "12 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Galectin Therapeutics Inc. \u2013 NASDAQ:GALT", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Galectin Therapeutics Inc. (NASDAQ: GALT). It indicates that financial data for this specific metric is provided by ICE Data Services and FactSet Research Systems Inc. and emphasizes the company's listin", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T16:10:53", "published_display": "07 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Galectin Therapeutics Inc. \u2013 LSX:A1JV3R", "summary": "This article provides the \"Price to sales forward\" for Galectin Therapeutics Inc. (LSX:A1JV3R) on the Lang & Schwarz Exchange. It appears to be a financial data page, indicating that the market is currently closed with no trades. The article is very shallow, providing minimal inf", "url": "https://www.tradingview.com/symbols/LSX-A1JV3R/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T21:40:11", "published_display": "06 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Galectin Therapeutics Inc. \u2013 NASDAQ:GALT", "summary": "This article provides a financial metric, the enterprise value to EBIT forward, for Galectin Therapeutics Inc. (NASDAQ: GALT). It indicates that the NASDAQ market for GALT was closed with no trades at the time of publication. The content appears to be a financial data point from ", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T08:42:34", "published_display": "06 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Galectin Therapeutics Inc (GALT)", "summary": "This article analyzes the historical performance of investing $1,000 in Galectin Therapeutics Inc (GALT) over different periods, detailing the potential returns and compound annual growth rates. It also provides a company overview, highlighting GALT's focus on developing therapie", "url": "https://www.stocktitan.net/tools/stock-return-calculator/GALT", "source_name": "Stock Titan", "published_at": "2026-07-04T02:09:05", "published_display": "04 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com", "summary": "This article reports on a Form 4 filing for Galectin Therapeutics Inc. the report is for the June 30th reporting period, and the stock ticker for Galectin Therapeutics is GALT, which experienced a -6.68% change. The article primarily shares this financial filing information witho", "url": "https://za.investing.com/news/stock-market-news/form-4-galectin-therapeutics-inc-for-30-june-93CH-4350915", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T12:40:52", "published_display": "01 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock", "summary": "Jamil Khurram, CMO of Galectin Therapeutics (NASDAQ:GALT), sold $262,083 worth of common stock and acquired $129,481 worth through option exercises between June 26-29, 2026. These transactions were executed under a Rule 10b5-1 plan, leaving him with no direct stock holdings. The ", "url": "https://www.investing.com/news/insider-trading-news/galectin-therapeutics-cmo-jamil-khurram-disposes-of-262083-in-stock-93CH-4769237", "source_name": "Investing.com", "published_at": "2026-07-01T01:39:33", "published_display": "01 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics director sells $150,890 in common stock By Investing.com", "summary": "Harold H. Shlevin, a director at Galectin Therapeutics Inc. (NASDAQ:GALT), sold 30,000 shares of common stock for approximately $150,890, following the acquisition of these shares through stock option exercises. The sales occurred under a Rule 10b5-1 trading plan and coincided wi", "url": "https://za.investing.com/news/stock-market-news/galectin-therapeutics-director-sells-150890-in-common-stock-93CH-4350910", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T01:11:58", "published_display": "01 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity", "summary": "Galectin Therapeutics director Harold H. Shlevin exercised stock options for 30,000 shares and simultaneously sold them in open-market transactions on June 26 and June 29, 2026. The sales, executed under a Rule 10b5-1 trading plan, netted approximately $151,000. Following these t", "url": "https://www.stocktitan.net/sec-filings/GALT/form-4-galectin-therapeutics-inc-insider-trading-activity-547e499f8e23.html", "source_name": "Stock Titan", "published_at": "2026-07-01T00:13:19", "published_display": "01 Jul 2026 00:13", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale", "summary": "Jamil Khurram, the Chief Medical Officer of Galectin Therapeutics (GALT), exercised and sold 52,037 shares of common stock in pre-planned transactions on June 26 and 29, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on February 2, 2026, and occurred at p", "url": "https://www.stocktitan.net/sec-filings/GALT/form-4-galectin-therapeutics-inc-insider-trading-activity-c0c363c06586.html", "source_name": "Stock Titan", "published_at": "2026-06-30T23:23:19", "published_display": "30 Jun 2026 23:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark", "summary": "Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 3000E Growth Benchmark. This inclusion is part of several recent additions to various Russell indices, including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000, Russell 2000 Value, Rus", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-3000e-growth-benchmark-ce7f5fdedb80f223", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T00:13:19", "published_display": "30 Jun 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark", "summary": "Galectin Therapeutics Inc. (NasdaqCM:GALT) has been added to the Russell Small Cap Comp Growth Benchmark, as well as several other Russell indices including the Russell 2500 Growth, Russell 2000, and Russell 3000E Index. This news follows recent positive developments for the comp", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd8ff72d", "source_name": "marketscreener.com", "published_at": "2026-06-29T20:41:18", "published_display": "29 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares", "summary": "Harold Shlevin, an affiliate of Galectin Therapeutics Inc. (NASDAQ: GALT), has filed a Form 144 indicating a proposed sale of 7,732 shares of common stock. This sale is linked to a stock option exercise from January 23, 2025, with the method noted as \"CASH UPON EXERCISE\" and a tr", "url": "https://www.stocktitan.net/sec-filings/GALT/144-galectin-therapeutics-inc-sec-filing-87b835136c54.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:18", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark", "summary": "Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 2500 Growth Benchmark as of June 29, 2026. This inclusion reflects the company's growth trajectory and highlights its focus on developing therapies for chronic liver disease and cancer. The biopharmaceutica", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-2500-growth-benchmark-ce7f5fdfda8ef520", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:41:18", "published_display": "29 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index", "summary": "Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 3000E Index. The company is a clinical-stage biopharmaceutical organization focused on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting galectin-3 protein", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-3000e-index-ce7f5fdedd8cf723", "source_name": "marketscreener.com", "published_at": "2026-06-29T06:40:40", "published_display": "29 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com", "summary": "This article reports on a Form 144 filing for GALECTIN THERAPEUTICS INC on June 26. It notes that the company's stock symbol is GALT and that its price has increased by 17.97%. The brief announcement also includes the Investing.com branding.", "url": "https://ng.investing.com/news/stock-market-news/form-144-galectin-therapeutics-inc-for-26-june-93CH-2576702", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T11:10:07", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT - Galectin Therapeutics Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Galectin Therapeutics Inc. (GALT), including key stock performance metrics, insider and institutional ownership, profitability ratios, and short interest data. It shows that GALT's last close was $4.64, with a negative doll", "url": "https://finviz.com/stock?t=GALT&p=m&ty=rv", "source_name": "Finviz", "published_at": "2026-06-27T00:13:19", "published_display": "27 Jun 2026 00:13", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals", "summary": "A Rule 144 notice for Galectin Therapeutics Inc (NASDAQ: GALT) indicates that Khurram Jamil has reported proposed sales of Common Stock, including recent dispositions of 568 shares on May 26, 2026, and 7,557 shares on June 23, 2026. The filing also details prior stock option exer", "url": "https://www.stocktitan.net/sec-filings/GALT/144-galectin-therapeutics-inc-sec-filing-329a8329d066.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:10:57", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] GALECTIN THERAPEUTICS INC SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Galectin Therapeutics Inc. (GALT). The filing details a proposed sale of 7,732 shares of common stock by an insider, acquired through a stock option exercise on January 23, 2025. The aggregate market value of the securities to be s", "url": "https://www.stocktitan.net/sec-filings/GALT/144-galectin-therapeutics-inc-sec-filing-b60ab6262df0.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:57", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN)", "summary": "This article provides financial actuals and estimates for Galectin Therapeutics Inc. (FWB:PHPN), detailing its income statement, balance sheet, cash flow, and valuation metrics. It also includes analyst forecasts for the stock price, earnings per share, revenue, and dividend info", "url": "https://www.tradingview.com/symbols/FWB-PHPN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:27", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Galectin Therapeutics Inc. (GALT) stock, highlighting a consensus analyst price target of $11.00. It covers various financial metrics, stock performance details, and frequently asked questions about GALT, including earnings, revenue, market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:09:57", "published_display": "26 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbDJnbmJOeWl1R2tqbUh0NUxDM1htdVNETVJIWTVzUVdRTlI5bS1TRmdsV2h4Y0dUT0tvRml2bk9WZnZmczJ1SU9CT3F3dkpQMzgtZFBEME5PQWpaY0JjUlRYUHVQeXg0QmRBMFRJOWY5Wno3cVV6dHR3ODBYZF9LRktsdEdURHg3aC1ZV1QxbnFMazZZWmI1MTgwMWpRREhnTjRmX04xT1d1MTM3SW9hM2kwMnRVejdRVTRr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRFM1TlQ2a1FLdlQxTFMxMXRud1kyYms5a1JLNXg2T2ZnRnd0TmJTWkRjNVItWDd4cS1Kak0zN1hZUm03NExOOWtvU2Rhclc5ckRyY2poLVdob0Q0czR4ZVVFdDJuQzhhcnJ0dVV0OXh2dEFrVlhIN09STjFjUXV2WGhxUDhPRXBiNDNuVmZCekF4cFdQWVhIemU1MzVvSlozdG9lM2pHMEp3SDlUV1ZLRWplY05RWWZEclV4SVVZU2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/galectin-therapeutics-says-fda-alignment-124435272.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:44:35+00:00", "published_display": "23 Jun 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/galectin-therapeutics-announces-positive-type-120000435.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:00:00+00:00", "published_display": "23 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics stock surges on FDA trial agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSkttUlJMUTZXbjE0VGd1YVo5M0ZCQWlmQ0xGUWpTT2xZSFBBeTZuelJDb1NLM25qaHpuZGRudmN4Rl9WaUVnZE9xUW1SNmNleVhSeVgyWERYS0JSZUxaUS1pWm1XRURJS2Q0UHFBanctd21vSFE5UFF6dWwxUmJNQ3BDclN5c3hsckU5ekVUSWV4amlIdFBYTlgtdC1jOV9IaGpQV2VScGNzM2w4ajZuTk1Kbk1laHdJOW9N?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPNnVpLXZpa1h0Z2Iwel9kSkhDLXJieFJRXzVIX2s2UXZIMFlHUDh3R2QxTURaN09jQXN5ZlZDUlhCbG9aSDVKWjVqMWhUT3pVOTFab3E1bE5pbW9uNjVJb1o2elB1RHZUZzA1TWk2ZHZfNFgxdHRQSzlaNnhIUDhSNHFRVEdOdC1DV0FEaGRZVW9qQW04Q2J1UDhtcnNfQkdObHNCSmpyWVFENWZ4UWdvZTJZSFNCaERKc194dGFVQ2pCMGxZZTY2Sm1BUXg0X1hOQkZkVHBPb1ZwWGlJUmM0c3l0RQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galecti, FDA agree on Phase 3 trial for MASH drug (GALT:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQcTNGRmd4VUJ2NlMtUXUwN0pGamY3S3lERXl3LTc0LXl0OFRZaWNGQ3pEbWl6TTZEM1RzMEM2a0xYOHlCZFpETGRuSTlnZ3NHa1lycnZiNGRkSE9qcllFQ0RYZ2I1VnEwVG4zVGxHLUJGRFdSdzRpNElXb2pUQmJRSmFXREtlUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT affiliate notifies sale of 8,125 shares (NASDAQ: GALT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQa1BhQUdscUdDdjR5TkJ1ZlduaUEtTE1XanlTQUlENnU3YkFQNEFldGw2V2Q2VXR0X1F0MnlYcFpzTGFmWlZrM05OVEpIdEplX1U3MU9USjF5MGNZdWtCa1hzOElubEJKM2pvTWt0eFVKR0tjbXRCcTFENzBmRG02U0RpOWktV2hacDA1eV9VazdHUjNXcUJSV19mUS1YMUhSUFdteQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin\u2019s Potential to Modify Disease Progression in Advanced MASH Cirrhosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galectin-therapeutics-presents-easl-2026-120000486.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:00:00+00:00", "published_display": "27 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galectin-therapeutics-reports-march-31-120000756.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:00:00+00:00", "published_display": "15 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galectin-therapeutics-announces-publication-navigate-120000541.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T12:00:00+00:00", "published_display": "11 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOMWdLQTBiYkI4N19UMldIWnZtSTBoVjJVNW44VURQNHd5YTdBVFp4Y180X1lwVVo2YlhFSHAxNlVBX3pRZlVpV3pLVTJpYkdPbEREVVEzWDh5RURWLWxYWWo0bGpkelk5TlgxWDZGNjBsWTFTRmYzRWk3V3JQRFlPbVp3N0V2Yy1nM19DRHYzM0RGRVFyQnlCbVdaTVVtZzZfS2xZUUZiYw?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics director Marc Rubin resigns from board", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbThQN2N5anNQTVdqbF9FT2oxLUlKNEtXS2xOaFF5QU1GcnpyRW44VElGWXlWXzMxcjBUcUc2cjVDWGYwX2h5akJNRXJoeUxPOUp0TDdoWnFoODhkM3VXeU1lRnRGaWJlNEZCMVlueEs2Wk8xelJmcHFCQ3hCODhFNHdiN0E2b1JjSWZIQzc4UERZalplQUlTa1pZbC1Qc1JmRmkybXE1Zk1GVk9QeXlybm9vN1I3dTg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freeman buys Galectin Therapeutics (GALT) shares worth $19,514", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUlJXV0wyLTR3MDJidnpqTVlWMkVUWG4xZk13d3BxSXZoYmZ1R2JKS2l0azQ1SXJ6WTd0czF2Q09zdmpXUTNFSTF3R0RTNDdFUlduenlKb1FPYTBuSDJwSXlwWWVMNDJaZzJmc3dyQ2wtT1lYcWhOdDhKU0ZGZ21JeGUwT0IwbWhhT2piRzVmSl9pNnBvU0FxVGxHbjhtOURqQzNEVlhXeHB4SEN0U0VRUlBrRk9WbFhBYWd1OExiTlQ?oc=5", "source_name": "Investing.com", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9xaE56WGZZamZWX2VGeWczMWM2UmpzODVRbXJuMHMzdWljS181NmdidHVjN1VtUjVCbHNNblZUUFBDNldHTzRTWVFUdUplS2RJWEQ4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:52:15+00:00", "published_display": "25 Apr 2025 00:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock", "summary": "Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., sold 16,250 shares of common stock for $83,284 on July 14, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options for the same number of shares at a lower price. Following the", "url": "https://www.investing.com/news/insider-trading-news/galectin-therapeutics-cmo-jamil-khurram-sells-83284-in-stock-93CH-4797135", "source_name": "Investing.com", "published_at": "2026-07-16T22:42:00", "published_display": "16 Jul 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan", "summary": "Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 each and subsequently sold all 16,250 shares at a weighted average price of $5.1252 on July 14, 2026. This transaction was conducted under a Rule 10b5-1 trad", "url": "https://www.stocktitan.net/sec-filings/GALT/form-4-galectin-therapeutics-inc-insider-trading-activity-cf346c04e766.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:42:00", "published_display": "16 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com", "summary": "This article reports on a Form 4 filing for Galectin Therapeutics Inc. on July 16, indicating a specific financial disclosure for the company. The stock symbol GALT is mentioned with a performance of -11.24%. The content primarily consists of market data and news headlines from I", "url": "https://ca.investing.com/news/stock-market-news/form-4-galectin-therapeutics-inc-for-16-july-93CH-4738612", "source_name": "Investing.com Canada", "published_at": "2026-07-16T21:42:00", "published_display": "16 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research", "summary": "Zacks Research has downgraded Galectin Therapeutics (NASDAQ:GALT) from \"hold\" to \"strong sell.\" This downgrade comes amidst mixed analyst ratings, with the company currently holding a consensus \"Reduce\" rating and a target price of $11.00. Galectin Therapeutics recently reported ", "url": "https://www.marketbeat.com/instant-alerts/galectin-therapeutics-nasdaqgalt-stock-rating-lowered-by-zacks-research-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T10:11:15", "published_display": "15 Jul 2026 10:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Galectin Therapeutics Inc. \u2013 NASDAQ:GALT", "summary": "This article from TradingView provides financial information for Galectin Therapeutics Inc. (NASDAQ: GALT). It specifically highlights the \"Price to book forward\" metric for the company. The rest of the content consists of navigation, market data sources, and copyright informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:11:15", "published_display": "15 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Galectin Therapeutics (GALT.US)$", "summary": "This page is a community post on moomoo about Galectin Therapeutics (GALT.US). It appears to be a user-generated comment or discussion point, not a formal article or analysis. The content primarily consists of navigation and promotional elements for moomoo itself, with the core m", "url": "https://www.moomoo.com/community/feed/galectin-therapeutics-galt-us-116904507342857", "source_name": "Moomoo", "published_at": "2026-07-12T16:40:53", "published_display": "12 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Galectin Therapeutics Inc. \u2013 NASDAQ:GALT", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Galectin Therapeutics Inc. (NASDAQ: GALT). It indicates that financial data for this specific metric is provided by ICE Data Services and FactSet Research Systems Inc. and emphasizes the company's listin", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T16:10:53", "published_display": "07 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Galectin Therapeutics Inc. \u2013 LSX:A1JV3R", "summary": "This article provides the \"Price to sales forward\" for Galectin Therapeutics Inc. (LSX:A1JV3R) on the Lang & Schwarz Exchange. It appears to be a financial data page, indicating that the market is currently closed with no trades. The article is very shallow, providing minimal inf", "url": "https://www.tradingview.com/symbols/LSX-A1JV3R/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T21:40:11", "published_display": "06 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Galectin Therapeutics Inc. \u2013 NASDAQ:GALT", "summary": "This article provides a financial metric, the enterprise value to EBIT forward, for Galectin Therapeutics Inc. (NASDAQ: GALT). It indicates that the NASDAQ market for GALT was closed with no trades at the time of publication. The content appears to be a financial data point from ", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T08:42:34", "published_display": "06 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Galectin Therapeutics Inc (GALT)", "summary": "This article analyzes the historical performance of investing $1,000 in Galectin Therapeutics Inc (GALT) over different periods, detailing the potential returns and compound annual growth rates. It also provides a company overview, highlighting GALT's focus on developing therapie", "url": "https://www.stocktitan.net/tools/stock-return-calculator/GALT", "source_name": "Stock Titan", "published_at": "2026-07-04T02:09:05", "published_display": "04 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com", "summary": "This article reports on a Form 4 filing for Galectin Therapeutics Inc. the report is for the June 30th reporting period, and the stock ticker for Galectin Therapeutics is GALT, which experienced a -6.68% change. The article primarily shares this financial filing information witho", "url": "https://za.investing.com/news/stock-market-news/form-4-galectin-therapeutics-inc-for-30-june-93CH-4350915", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T12:40:52", "published_display": "01 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock", "summary": "Jamil Khurram, CMO of Galectin Therapeutics (NASDAQ:GALT), sold $262,083 worth of common stock and acquired $129,481 worth through option exercises between June 26-29, 2026. These transactions were executed under a Rule 10b5-1 plan, leaving him with no direct stock holdings. The ", "url": "https://www.investing.com/news/insider-trading-news/galectin-therapeutics-cmo-jamil-khurram-disposes-of-262083-in-stock-93CH-4769237", "source_name": "Investing.com", "published_at": "2026-07-01T01:39:33", "published_display": "01 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics director sells $150,890 in common stock By Investing.com", "summary": "Harold H. Shlevin, a director at Galectin Therapeutics Inc. (NASDAQ:GALT), sold 30,000 shares of common stock for approximately $150,890, following the acquisition of these shares through stock option exercises. The sales occurred under a Rule 10b5-1 trading plan and coincided wi", "url": "https://za.investing.com/news/stock-market-news/galectin-therapeutics-director-sells-150890-in-common-stock-93CH-4350910", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T01:11:58", "published_display": "01 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity", "summary": "Galectin Therapeutics director Harold H. Shlevin exercised stock options for 30,000 shares and simultaneously sold them in open-market transactions on June 26 and June 29, 2026. The sales, executed under a Rule 10b5-1 trading plan, netted approximately $151,000. Following these t", "url": "https://www.stocktitan.net/sec-filings/GALT/form-4-galectin-therapeutics-inc-insider-trading-activity-547e499f8e23.html", "source_name": "Stock Titan", "published_at": "2026-07-01T00:13:19", "published_display": "01 Jul 2026 00:13", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale", "summary": "Jamil Khurram, the Chief Medical Officer of Galectin Therapeutics (GALT), exercised and sold 52,037 shares of common stock in pre-planned transactions on June 26 and 29, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on February 2, 2026, and occurred at p", "url": "https://www.stocktitan.net/sec-filings/GALT/form-4-galectin-therapeutics-inc-insider-trading-activity-c0c363c06586.html", "source_name": "Stock Titan", "published_at": "2026-06-30T23:23:19", "published_display": "30 Jun 2026 23:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark", "summary": "Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 3000E Growth Benchmark. This inclusion is part of several recent additions to various Russell indices, including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000, Russell 2000 Value, Rus", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-3000e-growth-benchmark-ce7f5fdedb80f223", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T00:13:19", "published_display": "30 Jun 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark", "summary": "Galectin Therapeutics Inc. (NasdaqCM:GALT) has been added to the Russell Small Cap Comp Growth Benchmark, as well as several other Russell indices including the Russell 2500 Growth, Russell 2000, and Russell 3000E Index. This news follows recent positive developments for the comp", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd8ff72d", "source_name": "marketscreener.com", "published_at": "2026-06-29T20:41:18", "published_display": "29 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares", "summary": "Harold Shlevin, an affiliate of Galectin Therapeutics Inc. (NASDAQ: GALT), has filed a Form 144 indicating a proposed sale of 7,732 shares of common stock. This sale is linked to a stock option exercise from January 23, 2025, with the method noted as \"CASH UPON EXERCISE\" and a tr", "url": "https://www.stocktitan.net/sec-filings/GALT/144-galectin-therapeutics-inc-sec-filing-87b835136c54.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:18", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark", "summary": "Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 2500 Growth Benchmark as of June 29, 2026. This inclusion reflects the company's growth trajectory and highlights its focus on developing therapies for chronic liver disease and cancer. The biopharmaceutica", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-2500-growth-benchmark-ce7f5fdfda8ef520", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:41:18", "published_display": "29 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index", "summary": "Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 3000E Index. The company is a clinical-stage biopharmaceutical organization focused on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting galectin-3 protein", "url": "https://www.marketscreener.com/news/galectin-therapeutics-inc-nasdaqcm-galt-added-to-russell-3000e-index-ce7f5fdedd8cf723", "source_name": "marketscreener.com", "published_at": "2026-06-29T06:40:40", "published_display": "29 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com", "summary": "This article reports on a Form 144 filing for GALECTIN THERAPEUTICS INC on June 26. It notes that the company's stock symbol is GALT and that its price has increased by 17.97%. The brief announcement also includes the Investing.com branding.", "url": "https://ng.investing.com/news/stock-market-news/form-144-galectin-therapeutics-inc-for-26-june-93CH-2576702", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T11:10:07", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT - Galectin Therapeutics Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Galectin Therapeutics Inc. (GALT), including key stock performance metrics, insider and institutional ownership, profitability ratios, and short interest data. It shows that GALT's last close was $4.64, with a negative doll", "url": "https://finviz.com/stock?t=GALT&p=m&ty=rv", "source_name": "Finviz", "published_at": "2026-06-27T00:13:19", "published_display": "27 Jun 2026 00:13", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals", "summary": "A Rule 144 notice for Galectin Therapeutics Inc (NASDAQ: GALT) indicates that Khurram Jamil has reported proposed sales of Common Stock, including recent dispositions of 568 shares on May 26, 2026, and 7,557 shares on June 23, 2026. The filing also details prior stock option exer", "url": "https://www.stocktitan.net/sec-filings/GALT/144-galectin-therapeutics-inc-sec-filing-329a8329d066.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:10:57", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] GALECTIN THERAPEUTICS INC SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Galectin Therapeutics Inc. (GALT). The filing details a proposed sale of 7,732 shares of common stock by an insider, acquired through a stock option exercise on January 23, 2025. The aggregate market value of the securities to be s", "url": "https://www.stocktitan.net/sec-filings/GALT/144-galectin-therapeutics-inc-sec-filing-b60ab6262df0.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:57", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN)", "summary": "This article provides financial actuals and estimates for Galectin Therapeutics Inc. (FWB:PHPN), detailing its income statement, balance sheet, cash flow, and valuation metrics. It also includes analyst forecasts for the stock price, earnings per share, revenue, and dividend info", "url": "https://www.tradingview.com/symbols/FWB-PHPN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:27", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Galectin Therapeutics Inc. (GALT) stock, highlighting a consensus analyst price target of $11.00. It covers various financial metrics, stock performance details, and frequently asked questions about GALT, including earnings, revenue, market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-GALT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:09:57", "published_display": "26 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbDJnbmJOeWl1R2tqbUh0NUxDM1htdVNETVJIWTVzUVdRTlI5bS1TRmdsV2h4Y0dUT0tvRml2bk9WZnZmczJ1SU9CT3F3dkpQMzgtZFBEME5PQWpaY0JjUlRYUHVQeXg0QmRBMFRJOWY5Wno3cVV6dHR3ODBYZF9LRktsdEdURHg3aC1ZV1QxbnFMazZZWmI1MTgwMWpRREhnTjRmX04xT1d1MTM3SW9hM2kwMnRVejdRVTRr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRFM1TlQ2a1FLdlQxTFMxMXRud1kyYms5a1JLNXg2T2ZnRnd0TmJTWkRjNVItWDd4cS1Kak0zN1hZUm03NExOOWtvU2Rhclc5ckRyY2poLVdob0Q0czR4ZVVFdDJuQzhhcnJ0dVV0OXh2dEFrVlhIN09STjFjUXV2WGhxUDhPRXBiNDNuVmZCekF4cFdQWVhIemU1MzVvSlozdG9lM2pHMEp3SDlUV1ZLRWplY05RWWZEclV4SVVZU2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/galectin-therapeutics-says-fda-alignment-124435272.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:44:35+00:00", "published_display": "23 Jun 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/galectin-therapeutics-announces-positive-type-120000435.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:00:00+00:00", "published_display": "23 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics stock surges on FDA trial agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSkttUlJMUTZXbjE0VGd1YVo5M0ZCQWlmQ0xGUWpTT2xZSFBBeTZuelJDb1NLM25qaHpuZGRudmN4Rl9WaUVnZE9xUW1SNmNleVhSeVgyWERYS0JSZUxaUS1pWm1XRURJS2Q0UHFBanctd21vSFE5UFF6dWwxUmJNQ3BDclN5c3hsckU5ekVUSWV4amlIdFBYTlgtdC1jOV9IaGpQV2VScGNzM2w4ajZuTk1Kbk1laHdJOW9N?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPNnVpLXZpa1h0Z2Iwel9kSkhDLXJieFJRXzVIX2s2UXZIMFlHUDh3R2QxTURaN09jQXN5ZlZDUlhCbG9aSDVKWjVqMWhUT3pVOTFab3E1bE5pbW9uNjVJb1o2elB1RHZUZzA1TWk2ZHZfNFgxdHRQSzlaNnhIUDhSNHFRVEdOdC1DV0FEaGRZVW9qQW04Q2J1UDhtcnNfQkdObHNCSmpyWVFENWZ4UWdvZTJZSFNCaERKc194dGFVQ2pCMGxZZTY2Sm1BUXg0X1hOQkZkVHBPb1ZwWGlJUmM0c3l0RQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galecti, FDA agree on Phase 3 trial for MASH drug (GALT:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQcTNGRmd4VUJ2NlMtUXUwN0pGamY3S3lERXl3LTc0LXl0OFRZaWNGQ3pEbWl6TTZEM1RzMEM2a0xYOHlCZFpETGRuSTlnZ3NHa1lycnZiNGRkSE9qcllFQ0RYZ2I1VnEwVG4zVGxHLUJGRFdSdzRpNElXb2pUQmJRSmFXREtlUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GALT affiliate notifies sale of 8,125 shares (NASDAQ: GALT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQa1BhQUdscUdDdjR5TkJ1ZlduaUEtTE1XanlTQUlENnU3YkFQNEFldGw2V2Q2VXR0X1F0MnlYcFpzTGFmWlZrM05OVEpIdEplX1U3MU9USjF5MGNZdWtCa1hzOElubEJKM2pvTWt0eFVKR0tjbXRCcTFENzBmRG02U0RpOWktV2hacDA1eV9VazdHUjNXcUJSV19mUS1YMUhSUFdteQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin\u2019s Potential to Modify Disease Progression in Advanced MASH Cirrhosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galectin-therapeutics-presents-easl-2026-120000486.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:00:00+00:00", "published_display": "27 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galectin-therapeutics-reports-march-31-120000756.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:00:00+00:00", "published_display": "15 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galectin-therapeutics-announces-publication-navigate-120000541.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T12:00:00+00:00", "published_display": "11 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOMWdLQTBiYkI4N19UMldIWnZtSTBoVjJVNW44VURQNHd5YTdBVFp4Y180X1lwVVo2YlhFSHAxNlVBX3pRZlVpV3pLVTJpYkdPbEREVVEzWDh5RURWLWxYWWo0bGpkelk5TlgxWDZGNjBsWTFTRmYzRWk3V3JQRFlPbVp3N0V2Yy1nM19DRHYzM0RGRVFyQnlCbVdaTVVtZzZfS2xZUUZiYw?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics director Marc Rubin resigns from board", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbThQN2N5anNQTVdqbF9FT2oxLUlKNEtXS2xOaFF5QU1GcnpyRW44VElGWXlWXzMxcjBUcUc2cjVDWGYwX2h5akJNRXJoeUxPOUp0TDdoWnFoODhkM3VXeU1lRnRGaWJlNEZCMVlueEs2Wk8xelJmcHFCQ3hCODhFNHdiN0E2b1JjSWZIQzc4UERZalplQUlTa1pZbC1Qc1JmRmkybXE1Zk1GVk9QeXlybm9vN1I3dTg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freeman buys Galectin Therapeutics (GALT) shares worth $19,514", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUlJXV0wyLTR3MDJidnpqTVlWMkVUWG4xZk13d3BxSXZoYmZ1R2JKS2l0azQ1SXJ6WTd0czF2Q09zdmpXUTNFSTF3R0RTNDdFUlduenlKb1FPYTBuSDJwSXlwWWVMNDJaZzJmc3dyQ2wtT1lYcWhOdDhKU0ZGZ21JeGUwT0IwbWhhT2piRzVmSl9pNnBvU0FxVGxHbjhtOURqQzNEVlhXeHB4SEN0U0VRUlBrRk9WbFhBYWd1OExiTlQ?oc=5", "source_name": "Investing.com", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galectin Therapeutics (GALT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9xaE56WGZZamZWX2VGeWczMWM2UmpzODVRbXJuMHMzdWljS181NmdidHVjN1VtUjVCbHNNblZUUFBDNldHTzRTWVFUdUplS2RJWEQ4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:52:15+00:00", "published_display": "25 Apr 2025 00:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 49, "sentiment_summary": {"positive": 10, "negative": 4, "neutral": 35, "score": 53, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 4.17, "latest_week": "2026-07-17", "one_week_move": 2.8, "four_week_move": 47.8, "twelve_week_move": 79.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.364235, "market_dynamics_buy_signal": false, "relative_strength": -1.24323, "fair_value_gap": 58.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.0, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.8% over one week, +47.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "Investing.com", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "Investing.com South Africa", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.8% over one week, +47.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock"}], "updated_at": "2026-07-18T16:23:13.437062+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}